SCHEMBL4473238

SCHEMBL4473238

CCc1cc2c(c(C)c1O)C(=O)CC1(CCC1)O2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.43
ATM Q13315 3/20 0.42
HTT P42858 2/20 0.42
ALDH1A1 P00352 5/20 0.39
HPGD P15428 3/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KLK7 P49862 1/20 0.37
ACACB O00763 1/20 0.35
PTPN1 P18031 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4462461 0.87 KDM4E (0.40) KDM4EATMHTTALDH1A1HPGD
SCHEMBL4466020 0.85 KDM4E (0.46) KDM4EATMHTTALDH1A1HPGD
SCHEMBL4482358 0.81 KDM4E (0.32) KDM4EATMHTTALDH1A1HPGD
SCHEMBL17762901 0.78 KDM4E (0.42) KDM4EATMHTTALDH1A1HPGD
SCHEMBL4507388 0.76 KDM4E (0.36) KDM4EATMHTTALDH1A1HPGD
SCHEMBL4880124 0.74 ALDH1A1 (0.36) KDM4EATMHTTALDH1A1HPGD
SCHEMBL4463485 0.73 KDM4E (0.30) KDM4E
SCHEMBL4463487 0.73 KDM4E (0.30) KDM4E
SCHEMBL4464207 0.73 PTPN1 (0.35) KDM4EATMHTTALDH1A1HPGD
SCHEMBL4481625 0.73 KDM4E (0.37) KDM4EATMHTTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 KDM4E 3310/4885ATM 3645/4885HTT 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.